Central nervous system (CNS) relapse is uncommon in patients with acute myeloid leukemia (AML) with the use of high-dose cytarabine containing chemotherapy regimens. The clinical and molecular features associated with a higher risk of CNS relapse are not well defined. We assessed the incidence and outcome of CNS relapses among 1245 patients with relapsed/refractory AML referred to our institution between 2000 and 2014. CNS leukemia relapse was observed in 51 patients (4.1%). Using a multivariate regression model and after adjusting for age, FLT3-ITD mutation (OR 5 2.33; P 5 .02) and elevated LDH (>1000 IU/L, OR 5 1.99; P 5 .04) were independent predictive factors for CNS relapse. Patients under 64 years of age with 0, 1, or 2 baseline adverse features had a probability of 3.8%, 7.0%-8.0%, and 13.9% for developing CNS disease, respectively. Our study identifies patients with AML at higher risk for CNS relapse in whom prophylactic CNS therapy may be warranted.
| I N T R O D U C T I O N
The high risk of central nervous system (CNS) relapse in acute lymphoblastic leukemia (ALL) became apparent with improvement in systemic therapy and overall survival. 1, 2 This necessitated the development of effective prophylactic CNS-directed therapy, which led to a substantial reduction in the overall incidence of CNS disease. The majority of children and half of adults with ALL who receive appropriate systemic and CNS therapies are cured. CNS relapse occurs in acute myeloid leukemia (AML) at low rates of 2%-8%, [3] [4] [5] [6] [7] except in inversion 16 AML where the incidence was 30% with standard-dose cytarabine regimens but was nearly eliminated with high-dose cytarabine regimens.
CNS prophylaxis does not appear to result in a significant benefit in adults in newly diagnosed AML. 8 This is likely attributable to the low incidence of CNS involvement in adult AML. 4, 6, 7, 9 In this study, our objective was to identify the clinical, biologic, and molecular features predictive of CNS relapse in patients with AML.
| MATERIALS A ND METHODS
We retrospectively reviewed data of patients with relapsed/refractory AML (excluding acute promyelocytic and core binding factor leukemia) Subsequently, competing risks regression model was used for the multivariate analysis for predicting CNS relapse
| R E S U LTS

| Patient characteristics
We reviewed the medical records of 1245 patients with relapsed/ refractory AML who were followed and treated at our institution. CNS leukemia was detected during follow-up in 51 patients (4.1%). Baseline characteristics of these 51 patients and the overall population are presented in Table 1 .
| CNS disease
CNS involvement was detected after a median of 7.6 months from initial diagnosis (range, 1 to 68 months 
| Multivariate analysis for CNS disease
All baseline variables were used in the univariate analysis. Younger patients (less than 64 years old), and those with FLT3-ITD mutation, high LDH (> 1000 IU/L), elevated WBC count (> 10 x 10 9 /L), without history of antecedent hematologic disorder, or with extramedullary disease at diagnosis had a higher incidence of CNS relapse (Table 2 ). In the multivariate regression model for CNS relapse, only age (<64 years; odds ratio 5 0.49, P 5 .04), mutated FLT3-ITD (odds ratio 5 2.16; P 5 .03), and higher LDH (odds ratio 5 1.87; P 5 .06) were independently associated with higher risk for CNS relapse (Table 3 ).
Since younger patients may live longer and are therefore at higher cumulative risk for CNS relapse, we subsequently performed a multi- FLT3-ITD mutation (odds ratio 5 2.33; P 5 .02) and higher LDH (odds ratio 5 1.99; P 5 .04) were the independent predictors for CNS relapse (Supporting Information Table S2 ).
| Predictive model for CNS relapse
A predictive scoring system was developed using age, FLT3-ITD mutation status and LDH among all patients. Since the relative risk for CNS relapse was similar for age, FLT3-ITD mutation status and a high LDH, we assigned an arbitrary value of 1 to each of them. Table 4 summarizes the results for patients under 64 years of age. Patients with no additional adverse feature (n 5 214; wild type FLT3-ITD and low LDH) had a probability of 3.8% for developing CNS disease; patients with one adverse feature (n 5 155) had a probability of 7.0%-8.0%; patients with two adverse features (n 5 55; both FLT3-ITD mutation and high LDH) had the highest probability of developing CNS disease (13.9%).
| DISCUSSION
The present study confirms that the occurrence of CNS relapse is rare in adults with AML, 6, 7, 9, 12, 13 with an incidence of 4.1% among 1245 patients with relapsed/refractory disease treated at our institution. This (20) FAB M4/M5 276 (22) 259 (22) 17 (33) FLT3-ITD mutation 160 (13) 145 (12) 15 (29) FLT3-D835 mutation 41 (3) 40 (3) 1 (2) NPM1 mutation 95 (8) 92 (8) 3 (6) RAS mutation 89 (7) 83 (7) The predictive scoring system was developed based on all patients (64 and <64 years of age).
